LENZ Therapeutics (LENZ) Cash from Investing Activities (2020 - 2026)

LENZ Therapeutics (LENZ) has reported Cash from Investing Activities for 7 consecutive years, with $33.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 75.56% year-over-year to $33.2 million; the TTM figure through Mar 2026 stood at -$61.4 million (up 60.03% YoY), while the FY2025 annual figure was -$75.7 million, up 51.02% from the prior year.
• Cash from Investing Activities grew to $33.2 million in Q1 2026 per LENZ's latest filing, from -$89.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $33.2 million in Q1 2026 and bottomed at -$170.7 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$27.6 million across 5 years, with a median of -$4.3 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 47307.22% — and 2024, when it soared 300100.0%.
• LENZ Therapeutics' Cash from Investing Activities stood at $13.5 million in 2022, then rose by 12.19% to $15.2 million in 2023, then sank by 178.18% to -$11.9 million in 2024, then sank by 657.06% to -$89.8 million in 2025, then soared by 136.92% to $33.2 million in 2026.
• Business Quant data shows LENZ's Cash from Investing Activities at $33.2 million in Q1 2026, -$89.8 million in Q4 2025, and -$4.3 million in Q3 2025.